Scholar Rock Announces European Medicines Agency Reviewing Apitegromab Marketing Authorisation Application To Treat Spinal Muscular Atrophy; Committee For Medicinal Products For Human Use Anticipated Later This Year If FDA Reclassifies Catalent Indiana
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin
Scholar Rock's medicine for a serious muscle disease is being reviewed by European regulators, which means they're checking if it's safe and works well. This review is a normal step that shows the company is trying to help patients in Europe, and it hints the medicine might actually have promise.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.